Interview: Mike Harsh on the evolution of Imaging and Imagion's role
Finfeed Archived Nov 18, 2019
With over 40 years’ experience in the healthcare diagnostic imaging industry, Imagion Biosystems (ASX:IBX) Board member Mike Harsh is one of the world’s most qualified people to speak about the evolution of diagnostics.
IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy
Next Investors Archived Oct 24, 2019
The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.
City of Hope receives US DoD grant with upside for Imugene
Finfeed Archived Oct 23, 2019
A US Department of Defense Grant has been awarded to renowned City of Hope researchers to fund research into gastric cancer, a disease that disproportionately affects US military service members, veterans, and their beneficiaries.
Imugene to demonstrate the benefits of combination tumor treatment
Finfeed Archived Oct 21, 2019
Imugene Limited (ASX:IMU) has provided a promising update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology.
GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer
Next Investors Archived Oct 02, 2019
Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).
Rhythm’s lead biomarker successfully differentiates between cancer and healthy samples
Finfeed Archived Sep 19, 2019
New antibodies for the key lead biomarker used in Rhythm Biosciences' (ASX: RHY) ColoSTAT® test can successfully differentiate between cancer and healthy samples, and the test has now been optimised.